BERLIN — The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalized with COVID-19.
WHO said Saturday it has “accepted the recommendation” from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.
WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir “produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.”
The agency adds that while there was no “solid evidence” of increased mortality for hospitalized patients given the drugs, there were “some associated safety signals in the clinical laboratory findings” of an associated trial.
WHO says the decision won’t affect possible trials on patients who aren’t hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.
LATEST ON THE CORONAVIRUS PANDEMIC:
- Going against FDA, Florida Surgeon General discourages use of mRNA COVID vaccines
- Lakeland Regional Health sees COVID-19 and flu cases double over the holidays
- Cruise passengers win class action lawsuit against Carnival after deadly COVID outbreak
- Say goodbye to the COVID vaccine card: The CDC has stopped printing them
- COVID conspiracies return in force, just in time for 2024